or the "Company†), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, res. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric†...

or the "Company†), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric†...

市场表现概览 - 多家公司股价与交易量出现显著异动 成为市场领涨者 包括Beasley Broadcast Group (BBGI) ASPAC III Acquisition Corp (ASPC)及其单位ASPCU Enveric Biosciences (ENVB) 和 Creative Global Technology Holdings (CGTL) [1] Beasley Broadcast Group (BBGI) - 股价飙升至17.74美元 涨幅达338.27% 交易量超过3500万股 远超平均水平 [2] - 公司为美国多地运营广播电台的多平台媒体实体 第三季度营收为5100万美元（截至2025年9月30日） [2] ASPAC III Acquisition Corp (ASPC) 及其单位ASPCU - ASPC股价涨至24.3美元 涨幅131.87% 交易量约287万股 [3] - ASPCU股价涨至24.11美元 涨幅129.40% 交易量约51,758股 [3] - 两家均为总部位于香港的空白支票公司 市场对其潜在并购活动抱有预期 推动了股价上涨 [3] Enveric Biosciences (ENVB) - 股价涨至10.15美元 涨幅71.61% 交易量超过3200万股 远超平均水平 [4] - 公司专注于开发用于癌症护理的大麻素药物 其EVM301系列分子获得专利授权后 盘后交易进一步大涨74% [4] Creative Global Technology Holdings (CGTL) - 股价涨至1.09美元 涨幅65.18% 交易量超过2100万股 [5] - 公司业务为采购和转售回收的消费电子设备 总部位于香港 公布了截至2025年3月31日的2025财年上半年未经审计财务业绩 [5] 市场驱动因素 - 投资者密切关注与公司行动 并购以及创新商业模式相关的未来发展 这些因素可能进一步影响股价表现 [6] - 市场动态性凸显 多个行业的公司经历了显著的波动 [6]

美股市场表现 - 美股盘中涨跌互现 道琼斯指数上涨超过200点 涨幅0.50%至47,799.21点 纳斯达克指数下跌0.18%至23,533.49点 标普500指数上涨0.11%至6,849.05点 [1] - 工业股板块领涨 涨幅达0.8% [1] - 信息技术股板块表现落后 下跌0.6% [1] 商品市场动态 - 原油价格下跌0.8%至每桶57.78美元 [4] - 黄金价格下跌0.3%至每盎司4,225.70美元 [4] - 白银价格上涨0.5%至每盎司61.150美元 [4] - 铜价上涨0.7%至每磅5.3550美元 [4] 全球其他市场 - 欧洲股市涨跌不一 欧元区STOXX 600指数微涨0.05% 西班牙IBEX 35指数上涨0.12% 英国富时100指数上涨0.23% 德国DAX 40指数下跌0.17% 法国CAC 40指数下跌0.45% [5] - 亚洲市场多数收跌 日本日经225指数下跌0.10% 香港恒生指数上涨0.42% 中国上证综指下跌0.23% 印度BSE Sensex指数下跌0.32% [6] 宏观经济数据 - 美国第三季度民用工人薪酬成本上涨0.8% 上一季度涨幅为0.9% [7] - 美国12月第一周抵押贷款申请量环比增长4.8% [9] 公司特定新闻 - Photronics Inc (PLAB) 股价飙升35%至34.66美元 因公司第四季度业绩超预期且第一季度指引高于分析师预估 [8] - Braze Inc (BRZE) 股价大涨16%至35.42美元 因公司在第三季度收入超预期后上调了2026财年调整后每股收益和销售指引 [8] - Enveric Biosciences, Inc. (ENVB) 股价暴涨78%至10.56美元 因这家马萨诸塞州生物技术公司就用于开发精神健康障碍潜在疗法的EVM301系列分子相关专利申请获得了美国专利商标局的授权通知书 [8] - AeroVironment, Inc. (AVAV) 股价下跌10%至252.56美元 因公司公布的业绩和指引喜忧参半 [8] - Mama's Creations Inc (MAMA) 股价下跌9%至13.03美元 尽管公司近期公布了乐观的第三季度财务业绩 [8] - Pomdoctor Limited (POM) 股价暴跌73%至1.4799美元 [8] 能源库存数据 - 截至12月5日当周 美国原油库存减少181.2万桶 而前一周为增加57.4万桶 市场预估为减少230万桶 [2][9]

47,635, up 22 points or 0.05%. S&P 500 futures rose to 6,856, up 0.11%. Nasdaq 100 futures added 24.50 points to 25,724.25, a gain of 0.10%. Traders remained focused on the Fed’s 2 p.m. ET statement and Chair Jerome Powell’s press conference, with the market pricing in roughly a 90% probability of a quarter-point rate cut, according to CME’s FedWatch. Markets broadly expect the Fed to deliver its third consecutive 25-basis-point cut. However, internal divisions within the FOMC have added tension to today’s ...

Enveric Biosciences Inc. (NASDAQ:ENVB) shares jumped 73.82% in after-hours trading on Tuesday, climbing to $10.29.Check out the current price of ENVB stock here. According to Benzinga Pro data, the stock closed on Tuesday at $5.92, down 2.47%.Patent Allowance AnnouncedThe Massachusetts-based biotech company received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application related to its EVM301 Series molecules, which are being developed as potential treatments for mental heal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended: September 30, 2025 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___ to ___ Commission File Number 001-38286 ENVERIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Enveric Biosciences, Inc. 245 First Street, Riverview II, ...

文章性质说明 - 该新闻稿包含基于适用证券法的前瞻性陈述和前瞻性信息 [1] - 这些陈述与未来事件或未来业绩相关 除历史事实陈述外的所有陈述均可能为前瞻性陈述或信息 [1] - 前瞻性陈述可能包括关于未来信念、计划、期望或意图的陈述 并基于管理层的信念以及管理层所作的假设和当前可获得的信息 [1]

公司进展 - 公司为生物技术公司Enveric Biosciences，专注于开发用于治疗精神和神经疾病的下一代神经可塑性小分子药物 [1] - 公司在先导候选药物EB-003的化学、制造和控制开发方面取得显著进展 [1] - 公司已实现扩大生产规模和为所需监管活动准备药物的重要步骤，推进了EB-003的研发进程 [1]